Recommended Seasonal Influenza Vaccines for Different Age Groups: United States, 2015–2016 Influenza Season
| Vaccine . | Trade Name . | Manufacturer . | Presentation . | Thimerosal Mercury Content, microgram of Hg/0.5-mL dose . | Age Group . |
|---|---|---|---|---|---|
| Inactivated | |||||
| IIV3 | Fluzone | Sanofi Pasteur | 5.0-mL multidose vial | 25 | ≥6 mo |
| IIV3 | Fluzone Intradermal | Sanofi Pasteur | 0.1-mL prefilled microinjection | 0 | 18–64 y |
| IIV3 | Fluzone HD | Sanofi Pasteur | 0.5-mL prefilled syringe | 0 | ≥65 y |
| IIV3 | Fluvirin | Novartis Vaccines and Diagnostics | 0.5-mL prefilled syringe | ≤1.0 | ≥4 y |
| 5.0-mL multidose vial | 25 | ≥4 y | |||
| IIV3 | Fluarix | GlaxoSmithKline | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| IIV3 | FluLaval | ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline) | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| 5.0-mL multidose vial | <25 | ≥36 mo | |||
| IIV3 | Afluria | bioCSL | 0.5-mL prefilled syringe | 0 | ≥9 ya |
| 5.0-mL multidose vial | 24.5 | ≥9 ya via needle/syringe 18–64 y via jet injector | |||
| ccIIV3 | Flucelvax | Novartis Vaccines and Diagnostics | 0.5-mL prefilled syringe | 0 | ≥18 y |
| IIV4 | Fluzone Quadrivalent | Sanofi Pasteur | 0.25-mL prefilled syringe | 0 | 6–35 mo |
| 0.5-mL prefilled syringe | 0 | ≥36 mo | |||
| 0.5-mL vial | 0 | ≥36 mo | |||
| 5.0-mL multidose vial | 25 | ≥6 mo | |||
| IIV4 | Fluzone Intradermal Quadrivalent | Sanofi Pasteur | 0.1-mL prefilled microinjection | 0 | 18–64 y |
| IIV4 | Fluarix Quadrivalent | GlaxoSmithKline | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| IIV4 | FluLaval Quadrivalent | ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline) | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| 5.0-mL multidose vial | <25 | ≥36 mo | |||
| Recombinant RIV3 | FluBlok | Protein Sciences | 0.5-mL vial | 0 | ≥18 y |
| Live attenuated | |||||
| LAIV4 | FluMist Quadrivalent | MedImmune | 0.2-mL sprayer | 0 | 2–49 y |
| Vaccine . | Trade Name . | Manufacturer . | Presentation . | Thimerosal Mercury Content, microgram of Hg/0.5-mL dose . | Age Group . |
|---|---|---|---|---|---|
| Inactivated | |||||
| IIV3 | Fluzone | Sanofi Pasteur | 5.0-mL multidose vial | 25 | ≥6 mo |
| IIV3 | Fluzone Intradermal | Sanofi Pasteur | 0.1-mL prefilled microinjection | 0 | 18–64 y |
| IIV3 | Fluzone HD | Sanofi Pasteur | 0.5-mL prefilled syringe | 0 | ≥65 y |
| IIV3 | Fluvirin | Novartis Vaccines and Diagnostics | 0.5-mL prefilled syringe | ≤1.0 | ≥4 y |
| 5.0-mL multidose vial | 25 | ≥4 y | |||
| IIV3 | Fluarix | GlaxoSmithKline | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| IIV3 | FluLaval | ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline) | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| 5.0-mL multidose vial | <25 | ≥36 mo | |||
| IIV3 | Afluria | bioCSL | 0.5-mL prefilled syringe | 0 | ≥9 ya |
| 5.0-mL multidose vial | 24.5 | ≥9 ya via needle/syringe 18–64 y via jet injector | |||
| ccIIV3 | Flucelvax | Novartis Vaccines and Diagnostics | 0.5-mL prefilled syringe | 0 | ≥18 y |
| IIV4 | Fluzone Quadrivalent | Sanofi Pasteur | 0.25-mL prefilled syringe | 0 | 6–35 mo |
| 0.5-mL prefilled syringe | 0 | ≥36 mo | |||
| 0.5-mL vial | 0 | ≥36 mo | |||
| 5.0-mL multidose vial | 25 | ≥6 mo | |||
| IIV4 | Fluzone Intradermal Quadrivalent | Sanofi Pasteur | 0.1-mL prefilled microinjection | 0 | 18–64 y |
| IIV4 | Fluarix Quadrivalent | GlaxoSmithKline | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| IIV4 | FluLaval Quadrivalent | ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline) | 0.5-mL prefilled syringe | 0 | ≥36 mo |
| 5.0-mL multidose vial | <25 | ≥36 mo | |||
| Recombinant RIV3 | FluBlok | Protein Sciences | 0.5-mL vial | 0 | ≥18 y |
| Live attenuated | |||||
| LAIV4 | FluMist Quadrivalent | MedImmune | 0.2-mL sprayer | 0 | 2–49 y |
Implementation guidance on supply, pricing, payment, CPT coding, and liability issues can be found at http://redbook.solutions.aap.org/selfserve/ssPage.aspx?SelfServeContentId=vaccine-policy-guidance.
Data sources: American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2014–2015. Pediatrics. 2014;134(5):e1503–e1519; and Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2015–2016 influenza season. MMWR Recomm Rep. 2015;64(30):818–825.
Age indication per package insert is ≥5 years; however, the Advisory Committee on Immunization Practices recommends Afluria not be used in children 6 months through 8 years of age because of increased reports of febrile reactions noted in this age group. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child 5 through 8 years of age who has a medical condition that increases the child’s risk of influenza complications, Afluria can be used; however, pediatricians should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine.